Bristol-Myers Squibb Announces U.S. FDA Approval of NULOJIX® (belatacept)

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food & Drug Administration has approved NULOJIX (belatacept).

Please see accompanying Full Prescribing Information, including Boxed WARNINGS at www.NULOJIX.com or www.bms.com.

NULOJIX is a registered trademark of Bristol-Myers Squibb.



CONTACT:

Bristol-Myers Squibb Company
Media:
Ken Dominski, 609-252-5251, [email protected]
Investors:
John Elicker, 609-252-4611, [email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo